Avalo Therapeutics (AVTX) Other Non-Current Assets (2014 - 2026)
Avalo Therapeutics (AVTX) posted Other Non-Current Assets of $183000.0 for Q1 2026, down 12.86% on a QoQ basis from $210000.0 in Q4 2025, and up 39.69% year-over-year from $131000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $183000.0 for Q1 2026.
- Quarterly Other Non-Current Assets rose 39.69% year-over-year to $183000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183000.0 (up 39.69% YoY) and the FY2025 annual result came in at $210000.0, up 60.31% from the prior year.
- Other Non-Current Assets was $183000.0 for Q1 2026 at Avalo Therapeutics, down from $210000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $227000.0 in Q1 2022 and bottomed at $131000.0 in Q4 2022.
- A 5-year average of $162235.3 and a median of $131000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 42.29% — and 2025, when it surged 60.31%.
- Avalo Therapeutics' Other Non-Current Assets stood at $131000.0 in 2022, then changed by 0.0% to $131000.0 in 2023, then changed by 0.0% to $131000.0 in 2024, then jumped by 60.31% to $210000.0 in 2025, then slipped by 12.86% to $183000.0 in 2026.
- Business Quant data shows AVTX's Other Non-Current Assets at $183000.0 in Q1 2026, $210000.0 in Q4 2025, and $210000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 183,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 183,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Sep 30, 2025 | 210,000.00 |
| Jun 30, 2025 | 210,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 131,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 131,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | 131,000.00 |
| Jun 30, 2023 | 131,000.00 |
| Mar 31, 2023 | 131,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Sep 30, 2022 | 181,000.00 |
| Jun 30, 2022 | 227,000.00 |
| Mar 31, 2022 | 227,000.00 |
| Dec 31, 2021 | 227,000.00 |
| Sep 30, 2021 | 227,000.00 |
| Jun 30, 2021 | 149,000.00 |